Pan-tumor MRD Study
Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers
The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to develop tests to better understand cancer, for example, to improve cancer detection and to assess the risk of cancer coming back.
Participants will receive routine standard of care from their doctor and their involvement is expected to last for approximately five and a half (5.5) years.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Anosheh Afghahi, MD
- Phone Number: 888-662-6367
- Email: anosheh.afghahi@paradigmhealth.ai
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35205
- Recruiting
- Alabama Oncology
-
Contact:
- Kailee Hawkins
- Phone Number: 919-368-3285
- Email: kailee.hawkins@alabamaoncology.com
-
Principal Investigator:
- Carter Capra
-
-
Arizona
-
Bullhead City, Arizona, United States, 86442
- Recruiting
- Mohtaseb Cancer Center and Blood Disorders
-
Principal Investigator:
- Hamdy Mohtaseb
-
Contact:
- Stephanye Vargas
- Phone Number: 928-219-4560
- Email: stephanye@azcancerandblood.com
-
Casa Grande, Arizona, United States, 85122
- Recruiting
- Cancer & Blood Specialists of Arizona
-
Contact:
- Robin Wilson
- Phone Number: 520-836-9800
- Email: robin.wilson@aoncology.com
-
Principal Investigator:
- Carlos Arce-Lara
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- Recruiting
- CARTI
-
Contact:
- Carla Randall
- Phone Number: 501-906-3012
- Email: Crandall@carti.com
-
Principal Investigator:
- Andrew Briggler
-
Springdale, Arkansas, United States, 72762
- Recruiting
- Highlands Oncology Group (HOG)
-
Principal Investigator:
- Joseph Beck
-
Contact:
- Tina Patrick
- Phone Number: 479-872-8130
- Email: tpatrick@hogonc.com
-
-
California
-
Glendale, California, United States, 91204
- Recruiting
- Los Angeles Cancer Network (LACN)
-
Contact:
- Robert Milford
- Phone Number: (323) 794-1132 Ext: 3734
- Email: robert.milford@lahomg.com
-
Principal Investigator:
- Peyman Salimi-Tari
-
Oxnard, California, United States, 93030
- Recruiting
- Ventura County Hematology Oncology Specialists
-
Contact:
- Cheryl Senour
- Phone Number: 805-485-8709 x 121
- Email: csenour@venturaoncology.com
-
Principal Investigator:
- Lynn Kong
-
San Diego, California, United States, 92123
- Recruiting
- Medical Oncology Associates of San Diego
-
Contact:
- Alexis Bustamante
- Email: abustamante@oncologysandiego.com
-
San Diego, California, United States, 92123
- Recruiting
- Medical Oncology Associates of San Diego (MOASD)
-
Contact:
- Amanda Somo
- Phone Number: (858) 637-7888 ext 224
- Email: asomo@oncologysandiego.com
-
Principal Investigator:
- James Coggan
-
Stockton, California, United States, 95204
- Recruiting
- Stockton Hematology Oncology Med Group
-
Contact:
- Lenzi Cook
- Phone Number: 209-938-3106
- Email: lcook@shomg.net
-
Principal Investigator:
- Sunny Phillip
-
-
Colorado
-
Englewood, Colorado, United States, 80113
- Recruiting
- The Melanoma and Skin Cancer Institute
-
Contact:
- Sydney Harris
- Phone Number: 720-316-8091 extn 101
- Email: sydney.harris@theskincancerinstitute.com
-
Principal Investigator:
- Ryan Weight
-
-
Florida
-
Coral Springs, Florida, United States, 33065
- Recruiting
- Oncology & Hematology Associates of West Broward
-
Principal Investigator:
- Sumit Sawhney
-
Contact:
- Margie Murillo
- Phone Number: 954 726 0035 x1230
- Email: margie.murillo@ohawb.com
-
Orange City, Florida, United States, 32763
- Recruiting
- Mid Florida Cancer Centers
-
Principal Investigator:
- Santosh Nair
-
Contact:
- Kiran Penta
- Phone Number: 386-538-3169
- Email: Kiran@aocorp.com
-
St. Petersburg, Florida, United States, 33709
- Recruiting
- Comprehensive Hematology Oncology (CHO)
-
Principal Investigator:
- Neeharika Makani
-
Contact:
- Raj Shah
- Phone Number: 727-344-6569 Ext 1036
- Email: rshah@comphemonc.com
-
-
Georgia
-
Atlanta, Georgia, United States, 30318
- Recruiting
- Piedmont Cancer Institute
-
Contact:
- Katie Adams
- Phone Number: 678-298-3238
- Email: kadams@piedmontcancerinstitute.com
-
Principal Investigator:
- Vasileios Assikis
-
-
Illinois
-
O'Fallon, Illinois, United States, 62269
- Recruiting
- Cancer Care Specialists of Illinois (CCSI)
-
Principal Investigator:
- James Wade
-
Contact:
- Kaitlynn Zeisset
- Phone Number: 618-589-9721
- Email: kzeisset@ccsci.net
-
Urbana, Illinois, United States, 61801
- Recruiting
- Carle Health
-
Contact:
- Christine Canfield
- Phone Number: (217) 326-0095
- Email: christine.canfield@carle.com
-
Principal Investigator:
- Christine Canfield
-
-
Kansas
-
Topeka, Kansas, United States, 66606
- Recruiting
- Cotton O'Neil Cancer Center [Stormont Vail]
-
Contact:
- Scott Harrison
- Phone Number: 785-270-4962
- Email: saharris@stormontvail.org
-
Principal Investigator:
- Mehmmod Hashmi
-
Wichita, Kansas, United States, 67214
- Recruiting
- Cancer Center of Kansas
-
Principal Investigator:
- Shaker Dakhil
-
Contact:
- Kristen Mazowiecki
- Phone Number: (316) 613-4326
- Email: kristen.mazowiecki@cancercenterofkansas.com
-
-
Kentucky
-
Corbin, Kentucky, United States, 40701
- Recruiting
- Baptist Health Corbin
-
Contact:
- Janie Platt
- Phone Number: 859.260.6406
- Email: Janie.platt@bhsi.com
-
Principal Investigator:
- Abigail Byrnes
-
Elizabethtown, Kentucky, United States, 42701
- Recruiting
- Baptist Health Hardin
-
Contact:
- Kristen Lerch
- Phone Number: 270-979-2686
- Email: Kristen.Lerch@bhsi.com
-
Principal Investigator:
- Christopher Burkeen
-
Lexington, Kentucky, United States, 40503
- Recruiting
- Baptist Health Lexington
-
Principal Investigator:
- Arvinda Padmanabhan
-
Contact:
- Tory Tincher
- Phone Number: 859.260.6464
- Email: Tory.Tincher@bhsi.com
-
Louisville, Kentucky, United States, 40207
- Recruiting
- Baptist Health Louisville
-
Principal Investigator:
- Wangjian Zhong
-
Contact:
- Kelly Strange
- Phone Number: 502.928.6103
- Email: Kelly.Strange@bhsi.com
-
-
Louisiana
-
Covington, Louisiana, United States, 70433
- Recruiting
- Pontchartrain Cancer Center
-
Principal Investigator:
- David Oubre
-
Contact:
- Ella Hunter
- Phone Number: 985-419 0025
- Email: ella@pcclouisiana.com
-
Shreveport, Louisiana, United States, 71105
- Recruiting
- Christus Health Highlands
-
Contact:
- Nancy Hassan
- Phone Number: 318.681.4763
- Email: nancy.senniah@christushealth.org
-
Principal Investigator:
- Neelima Chintapalli
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49546
- Recruiting
- The Cancer & Hematology Centers (CHC)
-
Contact:
- Maci Deboer
- Phone Number: (616) 954-5550 Ext. 1925
- Email: mdeboer@hcwm.com
-
Principal Investigator:
- Joy Bartholomew
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic
-
Contact:
- Lauren Helgeson
- Phone Number: 507-266-3718
- Email: helgeson.lauren@mayo.edu
-
Principal Investigator:
- Lisa Boardman
-
-
Missouri
-
Springfield, Missouri, United States, 65807
- Recruiting
- Cox Health
-
Contact:
- Tala Abu Zahra
- Phone Number: 417-269-7114
- Email: Tala.AbuZahra@coxhealth.com
-
Principal Investigator:
- Rajesh Banderudrappagari
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68516
- Recruiting
- Cancer Partners of Nebraska
-
Contact:
- Candice Toombs
- Phone Number: 402-327-7363
- Email: candicet@cancerpartners.com
-
Principal Investigator:
- Stacey Knox
-
-
New Mexico
-
Farmington, New Mexico, United States, 87401
- Recruiting
- San Juan Oncology Associates
-
Principal Investigator:
- Sardar Imam
-
Contact:
- Jessica Barnes
- Phone Number: (505)564-6850 ext 875
- Email: jessica@sjonc.com
-
-
New York
-
Binghamton, New York, United States, 13905
- Recruiting
- Guthrie Lourdes Memorial Hospital (GLMH)
-
Principal Investigator:
- Beka Aroshidze
-
Contact:
- Colleen English
- Phone Number: (607)798-5734
- Email: colleenh.english@guthrie.org
-
Shirley, New York, United States, 11967
- Recruiting
- New York Cancer & Blood Specialists
-
Principal Investigator:
- Richard Zuniga
-
Contact:
- Stella Smaragdas
- Phone Number: 631-675-5075
- Email: ssmaragdas@nycancer.com
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28207
- Recruiting
- Carolina Oncology Specialists
-
Principal Investigator:
- Justin Favaro
-
Contact:
- Tine Ekhaiyeme
- Phone Number: 704-342-1900 Ext 1126
- Email: aekhaiyeme@carolinaonco.com
-
Goldsboro, North Carolina, United States, 27534
- Recruiting
- Southeastern Medical Oncology Center (SMOC)
-
Contact:
- Mackenzie Lupton
- Phone Number: 919-429-4318
- Email: mlupton@cancersmoc.com
-
Principal Investigator:
- Samer Kasbari
-
Wilson, North Carolina, United States, 27893
- Recruiting
- Regional Medical Oncology Center
-
Principal Investigator:
- Keith Lerro
-
Contact:
- Meredith Best
- Phone Number: (252) 991-5261
- Email: meredith.best@regionaloncology.com
-
-
Ohio
-
Canton, Ohio, United States, 44718
- Recruiting
- Gabrail Cancer Center
-
Principal Investigator:
- Nashat Gabrail
-
Contact:
- Carrie Smith
- Phone Number: 330-417-8231
- Email: csmith@gabrailcancercenter.com
-
Maumee, Ohio, United States, 43437
- Recruiting
- Taylor Cancer Research Center
-
Contact:
- Jennifer Martinez
- Phone Number: ext 4134 419-479-5605
- Email: jmartinez@toledoclinic.com
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74129
- Recruiting
- Oklahoma Cancer Specialists and Research Institute (OCSRI)
-
Contact:
- Stephanie Sandoval
- Phone Number: 918-568-6759
- Email: stephanie.sandoval@ocsri.org
-
Principal Investigator:
- Scott Cole
-
-
Oregon
-
Portland, Oregon, United States, 97201
- Recruiting
- Oregon Health & Science University (OHSU)
-
Principal Investigator:
- Nima Nabavizadeh
-
Contact:
- Francis DeAsis
- Phone Number: (503) 418-8155
- Email: deasis@ohsu.edu
-
-
Pennsylvania
-
Lancaster, Pennsylvania, United States, 17601
- Recruiting
- Lancaster General Hospital (UPenn)
-
Contact:
- Susan Tollett
- Phone Number: 717-544-0511
- Email: susan.tollett@pennmedicine.upenn.edu
-
Principal Investigator:
- Efrat Dotan
-
Sayre, Pennsylvania, United States, 18840
- Recruiting
- Guthrie Foundation
-
Contact:
- Jackie Cole
- Phone Number: (570)887-6071
- Email: jacqueline.cole@guthrie.org
-
Principal Investigator:
- Rebekah Macfie
-
York, Pennsylvania, United States, 17403
- Recruiting
- Cancer Care Associates of York (CCAY)
-
Principal Investigator:
- Chanh Huynh
-
Contact:
- Clarissa Vega
- Phone Number: 717-741-9229 EXT: 147
- Email: cvega@cancercareyork.com
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- Onocology Consultants P.A. (Oncology Consultants [OC Houston])
-
Principal Investigator:
- Julio Peguero
-
Contact:
- Marisol Dominguez
- Phone Number: (832) 333-1480
- Email: marisol.dominguez@aoncology.com
-
Kingwood, Texas, United States, 77339
- Recruiting
- Community Clinical Trials
-
Principal Investigator:
- Saleha Sajid
-
Contact:
- Kemi Stewart
- Phone Number: 325-298-7478
- Email: kemi@communityclinicaltrials.com
-
Texarkana, Texas, United States, 75503
- Recruiting
- Christus St. Michael's
-
Principal Investigator:
- Sunil Patel
-
Contact:
- Kimberly Everett
- Phone Number: 903-614-6885
- Email: kimberly.everett@christushealth.org
-
-
Virginia
-
Richmond, Virginia, United States, 23229
- Recruiting
- Virginia Cancer Institute
-
Contact:
- Christine Mathews
- Phone Number: 1-804-287-3000 ext 1260
- Email: cmathews@vacancer.com
-
Principal Investigator:
- Susan Moore
-
-
Washington
-
Tacoma, Washington, United States, 98405
- Recruiting
- Northwest Medical Specialties (NWMS)
-
Contact:
- Erma Sanders
- Phone Number: 253-428-8700
- Email: esanders@nwmsonline.com
-
Principal Investigator:
- Manas Agastya
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Study participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors
Description
Eligibility Criteria:
-
Age 18 years or older.
-
Confirmed histological or cytological diagnosis of a malignant solid tumor that is either specified in one of the pre-defined tumor cohorts or meets the enrollment criteria for the Mix of Solid Tumors (MOST) cohort (Table 1).
-
Eligible for curative intent therapy, with surgical resection of cancer planned.
a. If surgical resection has occurred, enrollment should occur within 3 months of surgical resection and before initiation of adjuvant therapy.
-
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2.
-
No systemic therapy for current cancer diagnosis administered before enrollment.
-
Willing and able to comply with required study procedures, including blood sample collection and primary tumor tissue submission from diagnostic biopsy or surgical excision.
-
Has completed all therapy (including endocrine therapy) 3 or more years ago for any previous invasive solid organ malignancy (with exception of nonmelanoma skin cancers) or hematologic malignancy. Individuals with a prior history of noninvasive (in situ) carcinomas may participate if they have received definitive treatment (no washout period required).
-
No concurrent diagnosis of another invasive cancer, except for nonmelanoma skin cancers.
-
No prior allogeneic hematopoietic stem cell transplant.
-
Able and willing to provide informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for the release of personal health information.
Cohort Specific Criteria
-
Muscle-invasive urothelial carcinoma of the bladder and Melanoma Cohorts: Stage II or operable III cancer:
-
Esophageal, Gastric/GEJ, and NSCLC Cohorts: Stage I, II, or operable III cancer.
-
Pancreatic Cohort: Stage I, II or operable III cancer, exocrine only disease.
-
MOST cohort: Stage II or operable stage III solid tumor diagnosis that meets eligibility criteria and is not included in the other cohorts.
The following tumor types are excluded:
-
Central nervous system (CNS) malignancies
-
Colorectal cancer
-
Breast cancer
-
Squamous cell skin cancer
-
Basal cell carcinoma
-
Gastrointestinal stromal tumors (GIST)
-
Thyroid cancer
-
Uveal melanoma
-
Low or intermediate grade neuroendocrine tumors
■ Eligible tumor types: High-grade neuroendocrine tumors, including neuroendocrine carcinomas, Merkel cell carcinomas, and small cell lung cancer are permissible
-
Hematologic cancers including multiple myeloma or other plasma cell dyscrasias, Hodgkin's lymphoma, non-Hodgkin's lymphoma, acute or chronic leukemias including chronic lymphocytic leukemia / small lymphocytic leukemia
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Muscle Invasive Urothelial Carcinoma of the Bladder (MIBC)
Muscle Invasive Urothelial Carcinoma of the Bladder (MIBC) |
routine standard of care Routine standard of care |
|
Esophageal
Esophageal cancer |
routine standard of care Routine standard of care |
|
Gastric and Gastroesophageal Junction (GEJ)
Gastric and Gastroesophageal Junction (GEJ) |
routine standard of care Routine standard of care |
|
Melanoma
Melanoma |
routine standard of care Routine standard of care |
|
Non-small cell lung (NSCLC)
Non-small cell lung (NSCLC) |
routine standard of care Routine standard of care |
|
Pancreatic (exocrine only)
Pancreatic (exocrine only) |
routine standard of care Routine standard of care |
|
Mix of Solid Tumors (MOST)
Mix of Solid Tumors (MOST) |
routine standard of care Routine standard of care |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Blood and tissue biospecimen registry
Time Frame: Observation from enrollment to 5.5 years after enrollment
|
To establish a blood and tissue biospecimen resource in participants with operable solid tumors, with clinical, lab, radiographic, and pathology annotation for the discovery, development, and validation of MRD assays. |
Observation from enrollment to 5.5 years after enrollment
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Digestive System Diseases
- Gastrointestinal Diseases
- Lung Diseases
- Head and Neck Neoplasms
- Neoplasms, Glandular and Epithelial
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Esophageal Diseases
- Lung Neoplasms
- Skin Diseases
- Carcinoma
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Neuroendocrine Tumors
- Nevi and Melanomas
- Skin Neoplasms
- Skin and Connective Tissue Diseases
- Esophageal Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Adenocarcinoma
- Melanoma
- Investigative Techniques
- Specimen Handling
- Clinical Laboratory Techniques
- Diagnostic Techniques and Procedures
- Diagnosis
- Punctures
- Surgical Procedures, Operative
- Blood Specimen Collection
Other Study ID Numbers
Other Study ID Numbers
- PHPE-07-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.